The mitogen-activated protein kinase (MAPK) pathway is a central regulator of gene expression, pro-survival signaling, and inflammation. However, the importance of MAPK pathway signaling in regulating microglia-mediated neuroinflammation in Alzheimer's Disease (AD) remains unclear. Here we examined the role of MAPK signaling in microglia using pre-clinical in-vitro and in-vivo models of AD pathology integrated with quantitative proteomics studies of postmortem human brains.
INTRODUCTION
Neuroinflammation is now well recognized to play a critical role in the pathogenesis of Alzheimer's disease (AD). As the primary immune cells of the brain, microglia are the key enactors of neuroinflammation in AD (Hickman et al, 2018; Lambert et al, 2013) . However, microglia can mediate beneficial and detrimental neuroinflammatory mechanisms during disease.
Indeed, because microglia are transcriptionally diverse and highly responsive to their environment (Dubbelaar et al, 2018) , they contextually respond to acute and chronic tissues disease states determined by both the primary disease mechanism and disease duration (Bachiller et al, 2018; Tay et al, 2017) . In general, detrimental consequences of microglial responses in AD are mediated by pro-inflammatory mechanisms, which include release of neurotoxic molecules (ROS, NO) , production of cytokines (IL1β, TNFα, IL6), phagocytosis of live neurons or of healthy synapses and dendrites, impaired phagocytic clearance of debris and pathological protein aggregates. Microglial activity can also promote pathogenesis via indirect mechanisms, such as dysregulation of astrocytic or oligodendroglial functions, which then impact neuronal health and survival (Block et al, 2007; Geraghty et al, 2019; Hagemeyer et al, 2017; Liddelow et al, 2017; Sellgren et al, 2019) . Selective inhibition of these pro-inflammatory responses without impacting homeostatic functions is the desired immune consequence of neuro-immunomodulatory therapies for AD. Therefore, defining critical regulators of homeostatic, disease-associated and proinflammatory microglial responses in AD is necessary for the development of effective neuroimmunomodulatory therapies for AD (Rangaraju et al, 2018b) .
Distinct microglial states and their immunological profiles are likely to be determined by upstream signaling events that are engaged when microglia are exposed to protein signals, cytokines, pathological proteins and oxidative stress in the setting of neuronal injury or neurodegeneration. Signaling pathways, such as the mitogen activated protein kinase (MAPK) family of proteins, are engaged very early in immune cells following signals that activate receptor tyrosine kinases (RTKs) (Cargnello & Roux, 2011) . The MAPK pathway includes over 60 proteins which can be broadly categorized into three families, namely the ERK, JNK, and p38 MAPK cascades (Yates et al, 2017) . These dynamic cascades are initiated via activation of a cell surface receptor, which triggers serial phosphorylation events by serine/threonine protein kinases, ultimately activating or suppressing transcriptional factors which in turn regulate gene expression (Arkun & Yasemi, 2018; Santos et al, 2007) . ERK signaling is initiated by RTKs that 7 Samples were normalized to total protein using Pierce bovine serum albumin (BSA) Protein Assay kit (ThermoFisher Scientific, Waltham, MA, USA) and normalized to 0.1µg in Bio-Plex lysis buffer. Phospho-signaling was quantified using the MAPK/SAPK Signaling 10-Plex Multiplex assay (Millipore Sigma, . Phosphorylation sites for the MAPK/SAPK as follows: ATF2 (Thr71), ERK (Thr185/Tyr187), HSP27* (Ser78), JNK (Thr183/Tyr185), c-Jun (Ser73), MEK1 (Ser222), MSK1 (Ser212), p38 (Thr180/Tyr182), p53* (Ser15) and STAT1 (Tyr707). Analytes marked with an asterisk have not been reported to be mouse-reactive and were removed from the analysis. The assay was read out using a MAGPIX instrument (Luminex, Austin, TX, USA).
NanoString transcriptomic profiling of microglia and statistical analyses: NanoString transcriptomic profiling of mRNA isolated from primary mouse microglia was performed as previously published (Gao et al, 2019) . Primary microglia were treated with the ERK inhibitor in the presence or absence of IFNγ. The cells were washed in 1x Diethyl pyrocarbonate-phosphate buffered saline (DEPC-PBS) and lysed in TRIzol (Invitrogen). RNA was extracted from the lysates using the nCounter Low RNA Input Kit, and a quality control assessment was performed to determine concentration and integrity of RNA (RIN scores >8 for all samples). 100 ng of RNA per sample was run using the nCounter Mouse Neuroinflammation Panel (770 genes). The resulting gene expression data was imported into nSolver Analysis Software (version 4.0). A quality control check was done to assess the technical performance of the assay, and background thresholding parameters were established as the median of negative control counts. Only genes for which >50% of samples exceeded this threshold (n=678) were included in the final analysis.
The expression of these genes was first normalized to the geometric mean of the positive controls and then normalized to the geometric mean of 12 housekeeping genes.
One-way analysis of variance (ANOVA) and Tukey's Honestly Significant Difference (Tukey's HSD) tests were performed for comparison across four groups for each transcript (R, version 3.5.1). Genes demonstrating differential expression across groups (ANOVA p<0.05) were included in K-means clustering analysis conducted using Morpheus (https://software.broadinstitute.org/morpheus) with a pre-defined cluster number of 5. Gene ontology (GO) enrichment analysis was then performed on the resulting clusters using GO-Elite (version 1.2.5), a software that identifies GO terms, KEGG pathway terms and Wikipathway terms that are enriched in lists of genes as compared to a reference list of genes (Zambon et al, 2012 ). In addition to K-means clustering, we also used t-weighted stochastic neighbor embedding (t-SNE) to visualize clusters of genes in two dimensions and determine whether known homeostatic microglia and disease-associated-microglia (DAM) genes mapped to specific gene clusters identified in our dataset. We used existing reference transcriptomes and network analyses to obtain lists of homeostatic and DAM genes (Keren-Shaul et al, 2017) and lists of genes specific to modules of co-expressed microglial genes that were identified using network analyses approaches (Rangaraju et al, 2018b) .
Immunohistochemistry (IHC) studies of ERK and phospho-ERK in mouse brain: We used fixed floating sections (20µm thick) of brain derived from wild-type/Cx3cr1-Yfp and 5xFAD/Cx3cr1-Yfp mice for immunofluorescence studies using established protocols described previously (Rangaraju et al, 2018a) . The sections were blocked with 8% normal horse serum for 1 h and incubated with primary antibodies (anti-Phospho-ERK1/2, 1:20, 10ug/mL or anti-ERK1/2, 1:20, 10ug/mL, and anti-GFP 1:100) at 4 overnight. Then, the sections were incubated with fluorophore-conjugated secondary antibodies for 1 h at room temperature (RT).
Following 4 washes, the sections were mounted with hard mounting medium (VectorLabs, H1500) and DAPI for nuclear labeling. Negative controls (unstained sections and secondary alone sections) were performed for each experiment. Immunofluorescence imaging was performed using 20x and 60x (oil immersion) objectives on a fluorescence microscope (Olympus BX51 and Camera: Olympus DP70) using FITC, PE and DAPI filters. Image processing was performed using ImageJ software.
Flow cytometry studies of microglia: Flow cytometric assays of microglia viability, amyloid β (Aβ) phagocytosis, and microglia-mediated neuronal phagocytosis were performed using in-vitro primary mouse microglia. To assess the viability of microglia under the experimental conditions used in the NanoString studies above, primary microglia were treated with the ERK inhibitor and/or IFNγ using the concentrations and durations described above. After 24 h of incubation at 37 , the cells were washed in 1x PBS and trypsinized for 15 min at 37 . The trypsin was quenched with DMEM with 10% FBS, and the cells were washed again in PBS and labelled with LIVE/DEAD Fixable Blue Stain in the dark at RT for 30 min. After washing with 2% normal horse serum and again with PBS, PE-Cy7 fluorophore-conjugated anti-mouse CD45 antibody was added to the microglia and allowed to incubate at RT in the dark for 30 min, after which the cells were washed in PBS. Compensation, gating, and data analysis for flow cytometry were performed according to previously established protocols (Rangaraju et al, 2018b) . Viability was measured as the proportion of cells that were weakly fluorescent with the fixable blue dye.
The effect of ERK inhibition and inflammatory stimulation on microglial phagocytosis of fluorescent fibrillar amyloid-β 42 (fAβ42) was determined through flow cytometry as previously described (Gao et al, 2019) . Briefly, fAβ42 peptide conjugated to HiLyte Fluor 488 was mixed with 1% NH 4 OH and diluted in 1xPBS to achieve a concentration of 100µM, after which it was incubated in the dark for 6 days at RT. Once primary microglia had been treated with the ERK inhibitor and/or IFNγ, they were incubated with 2uM of fAβ42-488 for 1 h at 37 . The cells were collected and subsequently labelled with anti-CD45, after which flow cytometry was performed. Phagocytosis was assessed by observing the second peak of fluorescence emitted by phagocytic microglia, which was previously confirmed to represent actin-dependent phagocytosis (Rangaraju et al, 2018b) .
To measure microglia-mediated neuronal phagocytosis, we performed microglia-neuron co-culture studies using mouse N2a neuroblastoma cells that were stably transduced to express GFP (Lenti-Ubc-GFP/FUGW backbone, Addgene #14883) and primary p0-3 mouse microglia and used flow cytometry to detect microglial uptake of GFP+ neuronal material as an indicator of phagocytosis of neurons. All GFP-N2a cells were washed twice with medium and allowed to grow to 70-80% confluence. 50,000 N2a cells were seeded into 12-well plates, and 24 h later, the medium was replaced with DMEM with 1% FBS and 10 µM retinoic acid to induce differentiation for 4 days (Namsi et al, 2018) . Meanwhile, primary microglia were cultured in the presence or absence of IFNγ (1µg/mL) and treated with the ERK inhibitor (or DMSO control) at the same concentrations used in our transcriptomic studies. After 4 days of N2a neuronal differentiation, fresh medium with 1% FBS replaced the differentiation medium in which the N2a cells grew, and 100,000 microglia were seeded into each of the wells containing differentiated N2a cells. The co-culture was incubated overnight and then trypsinized for 2 min at 37 to harvest the cells for antibody staining. The cells were washed in 1% FBS media and again in PBS and labelled with LIVE/DEAD indicator (fixable blue) and anti-CD45 (PC-Cy7).
Microglial phagocytosis of neuronal cells was assessed by determining GFP positivity in microglia via flow cytometric analysis and appropriate negative controls (microglia without neurons). We compared the proportion of live CD45+ microglia that were also positive for GFP, across all the treatment conditions. In parallel, we also measured the proportion of live N2a-GFP+ cells in the co-culture by flow cytometry. These experiments were performed in biological triplicate.
Flow cytometric measurement of phospho-ERK1/2 expression was performed in acutelyisolated CNS mononuclear cells derived from wild-type and 5xFAD mice. Acutely-isolated CNS mononuclear cells were labeled with fluorophore-conjugated mAbs against CD11b (APC-Cy7) and CD45 (PE-Cy7), then fixed with fixation buffer for 10 min at RT. They were then permeabilized with cold methanol for 30 min at 4°C in the dark and blocked with Fc block (Biolegend Cat #553142) for 30 min. The cells were then incubated with primary anti-pERK1/2
(1:100) or anti-ERK (1:20) for 30 min followed by a secondary antibody (Goat anti-rabbit-FITC, Human post-mortem brain quantitative proteomics data: Two post-mortem brain proteomic datasets were used for analyses, with cases obtained from the Goizueta Alzheimer's Disease
Research Center at Emory. The first is a published dataset in which dorsolateral prefrontal cortex from 10 non-disease controls, 10 AD cases, 10 with Parkinson's disease (PD) and 10 with both 
RESULTS
Phosphorylated ERK and p38 MAPK is increased in microglia isolated from 5xFAD mice.
MAPKs are comprised of three broad sub-families of signaling proteins, namely ERK, JNK and p38 pathways ( Figure 1a ). We hypothesized that chronic microglial activation in models of neurodegeneration may be characterized by signaling via distinct MAPK pathways. To determine whether MAPK signaling is chronically up-regulated in microglia in a mouse model of AD pathology, we used magnetic associated cell sorting (MACS) columns to acutely isolate CD11b+ brain myeloid cells from adult (6-7 mo old) wild-type and age-and sex-matched 5xFAD mice that exhibit accelerated accumulation of Aβ pathology in the brain. CD11b + brain myeloid cells are comprised primarily (>95%) of microglia and a small proportion of CNSinfiltrating and perivascular blood-derived monocytes/macrophages (Rangaraju et al, 2018b) . To broadly interrogate phospho-signaling within the MAPK pathway in CD11b+ microglia, we lysed the isolated microglia and used a Luminex multiplexed immunoassay (Millipore) quantify phosphorylation of 9 proteins within the MAPK pathway ( Figure 1b ). We simultaneously quantified signaling within whole brain samples obtained from the frontal cortex ( Figure 1b) where Aβ pathology is abundant in 5xFAD mice. As compared to microglia isolated from WT mice, 5xFAD mouse microglia exhibited increased activation of ERK signaling, indicated by increased pERK1/2 and trend towards increased levels of pMEK1, an upstream ERK activator.
Increased p38 MAPK activation was also observed indicated by higher p-p38 levels in 5xFAD microglia ( Figure 1c ). Unlike microglia, we did not observe any differences in MAPK signaling in whole brain (Figure 1d ), suggesting that there are specific differences in microglial signaling in 5xFAD mice that are not broadly exhibited across the brain. These findings provide evidence for increased activation of specific MAPKs in microglia in 5xFAD mice.
To ascertain the expression levels of MAPKs at the total protein level in mouse microglia, we assessed the relative abundance of total MAPK proteins (as compared to non-MAPK proteins) in recently published proteomic datasets obtained from purified mouse microglia as well as BV2 mouse microglia. In total, 60 genes/proteins have been classified as belonging to the family of MAPK cascades (Supplemental Table 1 ) and this list of proteins was cross-referenced against two published microglial proteomes (Yates et al, 2017) . 17 MAPK proteins (total protein levels) were identified in acutely isolated CD11b+ microglia from WT, 5xFAD and LPS-treated WT mice (Figure 2a ), while 10 MAPK proteins were identified in BV2 microglia ( Figure 2b ). Interestingly, relative abundance of ERK proteins were highest in both acutely-isolated mouse microglia (Figure 2a ), as well as in BV2 microglia (Figure 2b ).
Compared to WT microglia, 5xFAD microglia showed lower total protein levels of Raf1 and MAP2K6, while microglia isolated from LPS-treated mice showed increased total levels of two ERK proteins (MAPK1 and MAPK3) and lower levels of Taok1 and Raf1 (Figure 2c ). Unlike our Luminex studies which showed alterations in levels of activated ERK phospho-proteins in 5xFAD microglia, total protein levels of ERK1 and ERK2 were not altered in 5xFAD microglia, indicating that activation of ERK signaling rather than increased protein expression is likely to occur in 5xFAD microglia. Consistent with this, immunofluorescence microscopy studies of wild-type and 5xFAD brains also confirmed no differences in total ERK protein levels ( Figure   2d ), while pERK1/2 expression was increased in microglia with activated morphology in 5xFAD brains (Figure 2e ). In flow cytometric studies of acutely-isolated brain myeloid cells (Figure 2f ), we also confirmed that intracellular pERK1/2 levels were increased in 5xFAD microglia as compared to wild-type microglia, whereas total ERK1/2 was equal between the groups ( Figure   2f -g).
In summary, our findings demonstrate that MAPK signaling proteins belonging to the ERK cascade are highly abundant in microglia and that microglia in AD mouse models exhibit up-regulation of ERK phospho-signaling, supporting critical roles for ERK signaling in regulating neuroinflammation in AD.
ERK signaling is a critical regulator of pro-inflammatory activation in microglia.
We recently reported that ERK signaling may be an important regulator of pro-inflammatory microglial activation. Based on our results showing increased ERK signaling in 5xFAD microglia and the relevance of ERK to human AD pathology, we next hypothesized that ERK is a key regulator of DAM gene expression, particularly those genes pertaining to proinflammatory responses that can be detrimental in the context of AD. To test this hypothesis, we exposed mouse primary microglial cultures isolated at postnatal day 0-3 to a selective ERK1/2 inhibitor (SCH772984, 1μM) in the presence or absence of IFNγ stimulation (1ng/mL) and
performed viability studies as well as NanoString transcriptomic profiling for 770 neuroinflammatory genes. Overall, ERK inhibition minimally impacted cell health and viability under our experimental conditions (Supplemental Figure S1 ).
Of 770 genes in the NanoString panel, 678 were included for final analysis after normalization ( Supplemental Table S2 ). One-way ANOVA identified 465 genes with differential 14 expression across all 4 groups (436 genes also met FDR<0.05 criteria), and K-means clustering of these differentially expressed genes revealed 4 main clusters of genes ( Figure 3a , Supplemental Table S3 ). Cluster 1 was comprised of genes negatively regulated by ERK under both unstimulated and IFNγ-stimulated conditions. Cluster 2-4 were all positively regulated by ERK signaling. Within these ERK-positively-regulated clusters, Cluster 2 was suppressed by IFNγ, Cluster 3 was upregulated by IFNγ and Cluster 4 was not affected by IFNγ. Among
Cluster 3 genes, we also observed that the effect of ERK inhibition was most pronounced in the presence of IFNγ. Most statistically significant and representative genes for each cluster are shown in Figure 3a .
To obtain a broad functional understanding of the genes involved in each cluster, we next performed GO enrichment analyses (GOElite) on each cluster using all included genes in the neuroinflammation panel as the reference. Cluster 1 genes were enriched for neuronal/synaptic and glutamatergic transcripts with generally low abundance. Cluster 2 was enriched for genes involved in IGF1 receptor signaling, negative regulation of apoptosis, cell differentiation and energy metabolism and integrin binding. Cluster 3 was enriched with genes involved in proinflammatory signaling and immune processes, cytokine activity and transcriptional factor activity in the nucleus. Cluster 4 was enriched with genes involved in DNA replication, cell division, cytokine secretion, ribosomal machinery and purine metabolism ( Figure 3b ). Additional KEGG and Wikipathway enriched terms are shown in Supplemental Table S4 . Since ERK signaling finally regulates transcription factor (TF) activity, we used bioinformatics approaches (Metacore, Thompson Reuters) to identify TFs down-stream of ERK activation that are likely to regulate gene expression in Cluster 2, 3 and 4 genes ( Supplemental table S5 Figure S2 ) and pro-inflammatory DAM genes, including Ccl2, Irf1, Tnf, Slamf9, and Cd69 (Supplemental Figure S3 ). We also calculated a synthetic eigenvalue to represent overall expression of homeostatic, anti-inflammatory DAM and pro-inflammatory DAM profiles across each experimental condition using previously identified hub genes (Kme>0.75) of each microglial profile that were present in our Nanostring dataset (Dai et al, 2018; Gao et al, 2019) . We confirmed that inhibition of ERK activity suppresses homeostatic, anti-inflammatory as well as pro-inflammatory DAM gene expression while IFNγ increases pro-inflammatory DAM and suppresses anti-inflammatory DAM gene expression ( Figure 4d ). A summary of the direction of regulation of each cluster by IFNγ and ERK activity is shown in Figure 4c . We also performed validation qRT-PCR studies using primary mouse microglia to confirm ERK-mediated regulation of several DAM genes (Apoe, Trem2, Tyrobp, Spp1) identified in Cluster 2 as well as pro-inflammatory genes (Tnf) identified in Cluster 3 (Supplemental Figure S4 ).
To summarize our findings from transcriptomic and in-vitro microglial functional studies, ERK appears to be important for homeostatic, protective as well as pathological responses mediated by microglia. However, the critical role for ERK in regulating pro-inflammatory immune responses appears to be most evident under pro-inflammatory conditions. This suggests that the role for microglial ERK in promoting neuroinflammatory disease mechanisms may be highly context dependent. While ERK activation in homeostatic microglia may regulate constitutive functions and mediate the effects of several trophic factors, ERK activation under disease-associated conditions, such as in AD, may regulate pro-inflammatory immune responses.
ERK signaling regulates microglial phagocytic function.
Having found that ERK signaling regulated diverse DAM-associated genes, we next asked whether or not ERK inhibition would modulate microglial phagocytic function. To test this, we used a flow cytometric assay of fluorescently labeled Aβ42 fibril phagocytosis. We observed that ERK inhibition reduced the ability of microglia to phagocytose Aβ42 fibrils regardless of stimulation by IFNγ (Figure 5a-b ). Since pro-inflammatory microglia can also mediate neurotoxicity via direct neuronal phagocytosis, we performed in-vitro microglia/neuronal coculture studies and determined the effect of IFNγ and ERK inhibition on microglia-mediated neuronal phagocytosis. N2a cells were stably transduced to express GFP and then differentiated with retinoic acid under low serum conditions for 4 days. Primary mouse microglia, which were treated with IFNγ and/or ERK inhibitor were then added to differentiated N2a-GFP cells for another 24 h, after which microglia were collected for flow cytometric studies to measure GFP positivity within microglia. First, we observed that addition of microglia, regardless of treatment, resulted in decreased viability in N2a cells, indicating that in-vitro cultured primary microglia induce some level of neurotoxicity, possibly due to baseline level of activation as a result of invitro culture conditions and serum exposure (Figure 5c ). Inhibition of ERK significantly reduced microglial phagocytosis of N2A cells with or without IFNγ treatment (Figure 5d ). These functional assays support a role for ERK in phagocytic activity, both for Aβ as well as neuronal phagocytosis.
A framework for ERK activation down-stream of receptor tyrosine kinases (RTKs) in homeostatic microglia and DAM.
Since ERK signaling is initiated by activation of receptor tyrosine kinases (RTKs) on the cell surface, it is likely that the predominant types of RTKs expressed by cells, are the key determinants of ERK activation (Figure 6a the NanoString panel and 28 demonstrated differential expression in our dataset, mapping to any one of the 5 gene clusters (Figure 7a , Supplemental Table S6 ). While there was no statistically significant over-representation of AD risk genes in any of the clusters, risk genes with highest MAGMA significance mapped to Cluster 2 (Cnn2, Ms4a4a, Mef2c, Cd33) and Cluster 4 (Bin1, Pilra, Ep300). Cluster 3 AD risk genes included Sqstm1, Lrrc25 and Nrp2. Of these 28 ERKregulated AD risk genes, 11 genes are specifically expressed in microglia (highlighted in Figure   7a with red asterisks).
To determine whether MAPK pathway protein expression and phospho-signaling is altered in human AD, we investigated two post-mortem brain quantitative proteomic datasets.
The first dataset was derived from 10 controls, 10 AD cases, 10 with Parkinson's disease and 10
with both AD and PD pathological features. Tandem mass tag proteomics was performed on brain tissues obtained from the dorsolateral pre-frontal cortex ( Supplemental Table S7 ). In this dataset, 33 MAPK proteins were identified and differential expression analyses comparing AD with control samples revealed increased expression of MAPK1 (ERK2) and MAPK3 (ERK1) in AD, while other MAPKs including MAPK8-10 (JNK1-3) were decreased in AD brains ( Figure   7b ). We also found that increased levels of MAPK1 (ERK2) and MAPK3 (ERK1) were only seen in brains with AD pathology while PD brains did not exhibit increased MAPK1 or MAPK3 levels (Figure 7c -e). We also observed strong associations between AD neuropathological grade (BRAAK stage) and protein levels of MAPK1 (R=0.45, p<0.005) and MAPK3 (R=0.59, p<0.005) (Figure 7d ,f). These findings from total protein expression data show that ERK signaling proteins are specifically increased in AD brains. However, these data do now confirm whether activation of ERK proteins are also increased.
We then turned to a phospho-proteomic dataset in which frontal cortex samples from 6 controls, 6 asymptomatic AD pathology and 6 symptomatic AD cases were used for quantitative TMT proteomics after purification of phosphopeptides on an immobilized metal affinity chromatography (IMAC) column. A comprehensive description and analysis of this phosphoproteomic dataset will be published separately and the expression data and methods have been deposited online at http://proteomecentral.proteomeexchange.org. Within this dataset, we obtained expression data for phosphopeptides that mapped to any of the known 60 MAPK family reference protein/gene list. This identified 127 phospho-peptides of which 57 peptides showed differential expression (unadjusted ANOVA p<0.05) across controls, asymptomatic AD and symptomatic AD cases (Figure 8 , Supplemental Table S8 ). K-means clustering of these differentially expressed peptides revealed distinct clusters of peptides with unique trajectories of change across stages of AD progression (control AsymAD AD) (Figure 8a) . Cluster 1 comprised of peptides with dose-dependent increase across the three groups, and Cluster 4 showed early and sustained increase, while Cluster 3 showed a delayed increase. Conversely, Clusters 2 showed decreased expression in clinical stages of AD pathology although the number of these peptides were relatively small. The overall trajectories of change for each cluster are presented in Figure 8b . Based on known biological functions of each MAPK protein, we found that 20 peptides (11 gene symbols) mapped to the ERK cascade, while 23 peptides (8 gene symbols) mapped to JNK, 8 peptides (3 gene symbols) mapped to p38, and 4 peptides mapped to MAPK proteins involved in cross talk between JNK and p38 MAPK cascades (Figure 8c ). To gain further insights into roles of differentially expressed phosphopeptides in each signaling pathway, we then mapped each phosphopeptide to known MAPK signaling pathways. ERKrelated peptides mapped to all levels of the ERK signaling cascade (RAF MEK MAPK RSK) (Figure 8d ). Within the 20 ERK-related phosphopeptides with differential expression in this dataset, we then identified key phosphosites in ERK-family proteins of AD relevance. Three RSK peptides (RPS6KA2 pS434 and pS402, and RPS6KA5 pS750) and RAF peptides (BRAF dual phosphorylated pS358+pS750 and ARAF pS157) were increased at least 1.5-fold in AD compared to controls, and 2 RSK phosphopeptides (RPS6KA2 pS434 and pS402) were also increased 1.5-fold in the asymptomatic stage of AD (Supplemental Table S8 ). Two phosphosites in ERK2 were also increased in AD (MAPK1/ERK2 pS284, MAPK1/ERK2 pS202). While little is known about pS284 and its impact on ERK activity, S202 in ERK2 is located at the activating lip in very close proximity to two phosphorylation sites that confer full ERK kinase activity (ERK2 T185/Y187), and a S202P mutation confers resistance to ERK inhibitors, suggesting that ERK phosphorylation at S202 may positively regulate ERK activation (Goetz et al, 2014) . In addition to ERK phosphopeptides, we also found that early signaling events in the JNK and p38 cascades represented by phosphopeptides were also differentially expressed in AD brains ( Supplemental table S8 ). To identify upstream triggers that may regulate these differentially expressed MAPK phosphopeptides in AD, we performed 20 pathway enrichment analysis using PANTHER and found that the majority of proteins were downstream of growth factor receptors and receptor tyrosine kinases (RTKs) such as PDGF, GnRH, FGF, EGF, TGF and VEGF receptors ( Supplemental table S9 ). These findings using cross-sectional human post-mortem brain data show unique patterns of ERK activation in asymptomatic and symptomatic stages of AD pathology, suggesting that differential flux through MAPK signaling pathways, specifically ERK, may underlie symptomatic progression and neurodegeneration. We have summarized these patterns of differential ERK signaling observed in our phoshoproteomic analyses, in Figure 9 . Overall, ERK signaling activation in human AD brains was consistent with our observations in the 5xFAD mouse model of Aβ pathology of AD.
DISCUSSION
Immune responses are orchestrated by early phospho-signaling events that follow activation of cell surface receptors. In turn, phospho-signaling results in regulated expression of groups of genes that together determine the immunological phenotype and function of the cell. Among the various immune signaling cascades that may regulate microglial functions, we focused on the MAPK family of signaling proteins in the 5xFAD pre-clinical AD model in order to identify pathologically relevant changes in MAPK pathway signaling in microglia that is responsible for pro-inflammatory immune activation in AD. Using Luminex analyses of phospho-proteins in acutely-isolated microglia, we found that among the three main classes of MAPKs, up-regulated ERK signaling was the most apparent in microglia isolated from mouse AD models. However, no significant changes in MAPK activation were observed in the whole brain, indicating that upregulated ERK activation is particularly characteristic of microglia in AD. Since ERK signaling is often transient following immune stimuli, our observation of significantly increased pERK1/2 levels in mouse microglia from AD models also suggests that ERK activation may be persistently elevated in AD, potentially as a result of sustained activation of ERK via agonists of RTKs.
In support of a disease-relevant role for ERK in AD, we also found that ERK proteins are highly abundant in microglia isolated from 5xFAD mice. Moreover, in-vitro experiments using primary microglia, revealed that inhibition of ERK strongly suppressed pro-inflammatory immune activation induced by IFNγ, which is an AD relevant pro-inflammatory cytokine (Wood et al, 2015; Zheng et al, 2016) . We also found that ERK signaling is important for homeostatic and constitutive microglial functions including phagocytosis of Aβ, and that it was required for neuronal phagocytosis, which is a potentially neurotoxic microglial function duration AD pathogenesis (Rajendran & Paolicelli, 2018) . ERK signaling was also found to be an upstream regulator of expression of several canonical DAM genes including Trem2 and Tyrobp, suggesting that ERK signaling may regulate the transition of homeostatic microglia to DAM, a phenotype commonly seen in AD and other neurodegenerative disease conditions. However, we did not observe any role for ERK signaling in regulation of microglial Apoe expression, Consistent with these important roles for ERK signaling in mouse microglia and in 5xFAD AD mice, we found that human AD is also characterized by increased ERK activation.
Our analyses of human proteomics data, including phospho-proteomics studies, confirmed that in-vivo. These novel approaches will also facilitate the development of RTK modulators that regulate ERK signaling dynamics to achieve desired neuroinflammatory microglial phenotypes.
Although we focused on ERK signaling in microglia, our Luminex studies also suggested increased activation of p38 MAPK as well as trends towards increased JNK activation in microglia from 5xFAD mice and human post-mortem brain proteomes also suggested activation of JNK and p38 MAPK pathways, although to a lesser extent than ERK. These data suggest that non-ERK MAPKs may also be relevant in regulating microglial functions in AD. Beyond these MAPKs, NFκB signaling is another key regulator of pro-inflammatory immune responses, which was not considered in our studies (Shih et al, 2015) . Unlike the robust effects of ERK inhibition observed in these studies, we previously found that inhibition of JNK or NFκB in microglia had minimal effects on the expression of selected homeostatic and DAM genes or on effects of proinflammatory stimuli in microglia (Gao et al, 2019) . Due to the limited yield of protein from acutely-isolated CD11b+ microglia from adult mice, we focused our efforts on ERK, although future studies will investigate the importance of other MAPKs, specifically p38 and JNK signaling pathways, in AD.
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This manuscript contains 4 Supplemental Figures
Supplemental Figure 1 . ERK inhibition exerts minimal impact on viability of microglia. Supplemental Table S1 . List of MAPK genes/proteins cross-referenced with published proteomic data sets. Supplemental Table S2 . NanoString transcriptomic dataset for 678 genes with ANOVA p-values.
Supplemental Table S3 . K-means clustering of 465 differentially expressed genes in NanoString dataset.
Supplemental (d-e) Immunofluorescence microscopy of WT and 5xFAD brains probing for total ERK1/2 and p-ERK1/2 proteins in microglia. CX3CR1-GFP/WT and CX3CR1-GFP/5xFAD mice (age 7-8 mo) were used for these studies (n=3 mice/group).
(f) Intra-cellular flow cytometric analysis of acutely-isolated CNS myeloid cells for p-ERK1/2 labeling. Gating strategy used is shown (top).
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